Clinical trial
Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption…
NCT00183261 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00183261 |
|---|---|
| Title | Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection |
| Official title | A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Acute Infection and Early Disease Research Program Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | MRKAd5 HIV-1 gag/pol/nef, MRKAd5 HIV-1 gag/pol/nef placebo |
| Enrollment | 25 |
| Start date | Mar 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Oct 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | Nov 1, 2021 |
| Countries | American Samoa, Australia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: